Latest Breaking News On - Bradley mcgregor - Page 3 : comparemela.com

T-DXd Proves Mettle in Multiple Solid Tumors

Data from ongoing DPT02 trial show broad activity in HER2-expressing advanced disease

United statesFort pierceDana farber cancer instituteBradley mcgregorEd susmanAmerican society of clinical oncologyAmerican society of oncologyUniversity of texas md anderson cancer centerFunda meric bernstamCancer centerAmerican society

AstraZeneca, Daiichi Drug Shows Signs It Could Treat a Wide Range of Tumor Types

The HER2 protein targeted by the approved cancer drug Enhertu is found on a wide range of tumors. Interim Phase 2 data reported at the annual meeting of the American Society of Clinical Oncology suggest the AstraZeneca and Daiichi Sankyo drug has potential to treat many of these cancers.

United statesDaiichi sankyoBradley mcgregorDana farber cancer instituteAmerican society of clinical oncologyUniversity of texas md anderson cancer centerLank centerAmerican societyFunda meric bernstamCancer centerGenitourinary oncologyWeight lossMedical devicesHealthcare innovationMedcity newsMedcity news

Dr McGregor on Next Steps For Cabozantinib Plus Atezolizumab in Advanced RCC

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

Bradley mcgregorDana farber cancer instituteHarvard medical schoolLank centerGenitourinary oncologyCancers symposiumOnclive tvGenitourinary cancersRenal cell carcinoma

Ipsen Pharma: Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Three-year data - with a median follow-up of 44 months - from the Phase III CheckMate -9ER trial demonstrate maintained overall survival benefits with Cabometyx plus nivolumab compared to sunitinib regardless

France generalUnited statesUnited kingdomDennis riedlBradley mcgregorMauricio burottoAntoine thiery vuilleminLaurence albigesPhilippe barthIpsen euronextPaul nathanTonik choueiriAnand sharmaBradford hill clinical research centerTakeda pharmaceutical companyEuropean union

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma

Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years follow-up in first-line advanced renal cell carcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

France generalUnited statesUnited kingdomSan franciscoIpsen pharmaBradley mcgregorSteven hildemannMauricio burottoAntoine thiery vuilleminLaurence albigesPhilippe barthIpsen euronextPaul nathanCraig marksviceTonik choueiriAnand sharma